NASDAQ: SSIISs Innovations International Inc Stock
$3.47-0.05 (-1.42%)
Updated Jun 16, 2026
SSII Price
$3.47
Fair Value Price
N/A
Market Cap
$694.46M
52 Week Low
$3.11
52 Week High
$11.87
P/E
-69.4x
P/B
12.74x
P/S
20.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$48.47M
Earnings
-$10.03M
Gross Margin
49.1%
Operating Margin
-10.11%
Profit Margin
-20.7%
Debt to Equity
0.66
Operating Cash Flow
-$15M
Beta
0.19
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SSII Overview
SS Innovations International, Inc., situated in Fort Lauderdale, Florida, focuses on the development of sophisticated robotic systems for surgical use. Their offerings encompass the SSI Mantra, a specialized surgical robot, and SSI Mudra, a suite of surgical instruments designed to facilitate various operations, including robotic cardiac surgery. The company also provides SSI Maya, a dedicated platform for robotic surgical interventions, along with OMNI 3D HD, which delivers a real-time, high-definition 3D perspective of the surgical field within the operating room.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SSII's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
SSII
Ranked#75 of 93
Ranked#75 of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.72 | A | |
| $37.55 | A | |
| $26.43 | A |
Be the first to know about important SSII news, forecast changes, insider trades & much more!
SSII News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SSII scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SSII is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SSII is poor value based on its book value relative to its share price (12.74x), compared to the US Medical Devices industry average (3x)
P/B vs Industry Valuation
SSII is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SSII due diligence checks available for Premium users.
Valuation
SSII price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-69.4x
Industry
20.94x
Market
13.25x
SSII price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.74x
Industry
3x
SSII is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SSII's financial health
Profit margin
Revenue
$11.1M
Net Income
-$3.6M
Profit Margin
-32.3%
SSII's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SSII's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$90.5M
Liabilities
$36.0M
Debt to equity
0.66
SSII's short-term assets ($66.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SSII's short-term assets ($66.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SSII's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
-$54.2k
Financing
$18.2M
SSII's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SSII vs Medical Device Stocks
Ss Innovations International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.